𝔖 Bobbio Scriptorium

✦ LIBER ✦

Selective CFAE Targeting for Atrial Fibrillation Study (SELECT AF): Clinical Rationale, Design, and Implementation

✍ Scribed by ATUL VERMA; PRASHANTHAN SANDERS; LAURENT MACLE; JEAN CHAMPAGNE; GIRISH M. NAIR; HUGH CALKINS; DAVID J. WILBER

Book ID: 109208656
Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 317 KB
Volume: 22
Category: Article
ISSN: 1540-8167
DOI: 10.1111/j.1540-8167.2010.01959.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Rivaroxaban—Once daily, oral, direct fac

Rivaroxaban—Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF study

📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 242 KB

Evaluation of the novel factor Xa inhibi

Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)

✍ Christian T. Ruff; Robert P. Giugliano; Elliott M. Antman; Sharon E. Crugnale; T 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 419 KB

Ximelagatran compared with warfarin for

Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V)

✍ Jonathan L Halperin 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 134 KB